62 results
Page 2 of 4
F-3/A
rusiw43
17 Jun 22
Shelf registration (foreign) (amended)
5:19pm
6-K
EX-99.1
tcies36 eeba
10 Jun 22
Current report (foreign)
6:05am
F-3/A
1ms9hg baa263q
20 May 22
Shelf registration (foreign) (amended)
6:54pm
6-K
8m2nckn 2r
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
6-K
EX-99.2
qs36 aye47
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
6-K
EX-99.1
6xf44q7z8lpxyvxke
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
F-3
62bq3n lf5
15 Apr 22
Shelf registration (foreign)
5:27pm
6-K
EX-99.1
mcbs0tm
31 Mar 22
Connect Biopharma Reports Full Year 2021 Financial Results
5:15pm
20-F
pu3degi
31 Mar 22
Annual report (foreign)
4:33pm
20-F
EX-4.11
l1di91npcxnrl7yufac
31 Mar 22
Annual report (foreign)
4:33pm
20-F
EX-4.12
71k1ure1a 4oxm
31 Mar 22
Annual report (foreign)
4:33pm
6-K
EX-99.1
7wuxh
16 Feb 22
Current report (foreign)
4:01pm
6-K
EX-99.1
3hotiw3qe x956
5 Jan 22
Current report (foreign)
5:24pm
6-K
EX-99.2
4hju0s 6c6
5 Jan 22
Current report (foreign)
5:24pm
6-K
w5fm6rq
5 Jan 22
Current report (foreign)
5:24pm
6-K
EX-99.1
ewnhq
19 Nov 21
Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis
4:01pm
6-K
9m8677ujk
19 Nov 21
Primary endpoint met with all three CBP-201 arms achieving significant improvements
8:00am
6-K
EX-99.1
wpvmkf9zfywb 575
19 Nov 21
Primary endpoint met with all three CBP-201 arms achieving significant improvements
8:00am
6-K
EX-99.1
p34vau fzjosqtbq
8 Sep 21
Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating
8:31am
6-K
EX-99.1
kl2yd8bbftg79zoog6
2 Sep 21
Connect Biopharma Announces First Patient Dosed in China Pivotal Trial
4:40pm